Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
Analyses have demonstrated that AEs are present in a range of systems, including cardiac, nervous, gastrointestinal, and musculoskeletal disorders. It should be noted, however, that the incidence and signal intensity of these AEs vary depending on the specific drug in question. In clinical practice, the selection of an appropriate drug and the monitoring of AEs should be tailored to the individual patient's and specific characteristics.
Authors
- Bifa Fan (ORCID: https://orcid.org/0000-0001-7340-4039)
- An-Xiang Liu
- Chen Li (ORCID: https://orcid.org/0000-0001-6110-3714)
- Yi Zhang (ORCID: https://orcid.org/0000-0002-6156-1894)
- Yifan Li (ORCID: https://orcid.org/0000-0001-8260-7719)
- Wenhui Liu (ORCID: https://orcid.org/0000-0002-7503-9386)
- Chunhua Liu (ORCID: https://orcid.org/0000-0002-7186-889X)
- Huimin Hu (ORCID: https://orcid.org/0009-0005-7225-2244)
- Peng Mao (ORCID: https://orcid.org/0000-0003-2209-7221)
- Qing Shi
Institutions
- Beijing University of Chinese Medicine (CN)
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1186/s10194-024-01913-0
- Citations
- 31
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 11.95